NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy
and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥
1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not
received prior systemic therapy in the metastatic or locally advanced setting. Eligible
subjects must have measurable disease according to RECIST 1.1. This Phase II study will
enroll up to 83 subjects.